The NITAG of Luxembourg has been informed of a reduction in the manufacturing capacity for the vaccines HAVRIX 1440 and HAVRIX JUNIOR 720 (GSK), used to protect adults and children against hepatitis A.The NITAG details the correct use of the proposed alternatives in advice number and states its recommendation concerning the risk on the shortage supply for hepatitis A vaccine.


  • Recommendation
  • Europe
  • Luxembourg
  • Hepatitis A